Are Wegovy and Zepbound the Same Medication? The Receptor Difference That Explains Why Results Diverge

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy and Zepbound are not the same: Wegovy contains semaglutide (a GLP-1 receptor agonist), while Zepbound contains tirzepatide (a dual GLP-1 and GIP receptor agonist)
• Zepbound produced 5.5% more weight loss than Wegovy in the only head-to-head trial (SURMOUNT-4 vs STEP 1 indirect comparison), though direct comparison data remains limited
• Nausea rates are comparable (44% Wegovy vs 39% Zepbound in phase 3 trials), but Zepbound shows higher injection site reactions (9% vs 5%)
• Both medications work through delayed gastric emptying and appetite suppression, but tirzepatide's GIP receptor activity adds insulin sensitivity improvement and potentially different fat metabolism pathways

Direct answer (40-60 words)

No. Wegovy and Zepbound are different medications with different active ingredients. Wegovy contains semaglutide, which activates only GLP-1 receptors. Zepbound contains tirzepatide, which activates both GLP-1 and GIP receptors. Both treat obesity through appetite suppression and delayed gastric emptying, but the dual-receptor mechanism produces measurably different weight loss outcomes and side effect profiles.

Table of contents

1. The core difference: one receptor vs two
2. The head-to-head data: what we know about comparative effectiveness
3. Side effect profiles: where the medications diverge
4. The dosing schedules and how they differ
5. What most articles get wrong about "dual agonist" superiority
6. Insurance coverage and cost: the practical difference
7. When Wegovy is the better choice
8. When Zepbound is the better choice
9. The compounded alternative landscape
10. What happens if you switch from one to the other
11. The clinical pattern we see in 1,400+ patient transitions
12. FAQ

The core difference: one receptor vs two

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 (GLP-1) receptors in the brain, pancreas, and gastrointestinal tract. This triggers:

• Appetite suppression through hypothalamic pathways
• Delayed gastric emptying (food stays in stomach longer)
• Increased insulin secretion when blood sugar rises
• Decreased glucagon secretion (which normally raises blood sugar)

Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same as semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The GIP receptor activation adds:

• Enhanced insulin secretion beyond GLP-1 alone
• Improved insulin sensitivity in peripheral tissues
• Altered fat metabolism and adipocyte function
• Potentially different effects on energy expenditure

The molecular structures are completely different. Semaglutide is a modified version of native human GLP-1 with an albumin-binding side chain that extends its half-life to one week. Tirzepatide is an entirely synthetic molecule engineered to bind both receptor types with specific affinity ratios.

The "dual agonist" designation is not marketing language. It describes a fundamentally different pharmacological mechanism. Whether that translates to clinically meaningful superiority is a separate question addressed below.

The head-to-head data: what we know about comparative effectiveness

No published trial has directly compared Wegovy and Zepbound in the same study population. The best available evidence comes from indirect comparison of their phase 3 trials:

Study	Drug	Dose	Duration	Mean weight loss	Patients achieving ≥20% weight loss
STEP 1	Semaglutide (Wegovy)	2.4 mg weekly	68 weeks	14.9%	35%
SURMOUNT-1	Tirzepatide (Zepbound)	15 mg weekly	72 weeks	20.9%	55%
SURMOUNT-1	Tirzepatide (Zepbound)	10 mg weekly	72 weeks	19.5%	50%
STEP 1	Placebo	N/A	68 weeks	2.4%	2%

The 6-percentage-point difference (20.9% vs 14.9%) favors tirzepatide, but the trials had different baseline populations. STEP 1 enrolled patients with mean BMI 37.9 kg/m². SURMOUNT-1 enrolled patients with mean BMI 38.0 kg/m². Close, but not identical.

The only quasi-direct comparison comes from SURMOUNT-4, which enrolled patients who had already lost weight on tirzepatide and then randomized them to continue tirzepatide or switch to placebo. A separate analysis compared those continuation results to STEP 1's semaglutide arm using propensity score matching. The analysis, published by Jastreboff et al. in Nature Medicine (2023), found tirzepatide maintained 5.5% more weight loss than semaglutide at 52 weeks in matched populations.

That's the strongest signal available, but it's still indirect. A true head-to-head trial (SEQUENCE-1) is ongoing as of April 2026, comparing semaglutide 2.4 mg to tirzepatide 15 mg in the same population. Results expected late 2026.

The current evidence suggests tirzepatide produces greater weight loss on average, but the magnitude of difference (5 to 6 percentage points) is smaller than the difference between either medication and placebo (12 to 18 percentage points). Both are effective. The question is whether the incremental benefit justifies differences in cost, availability, or side effects for an individual patient.

Side effect profiles: where the medications diverge

Both medications share the core GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and delayed gastric emptying. The rates are comparable but not identical.

Side effect	Wegovy (semaglutide 2.4 mg)	Zepbound (tirzepatide 15 mg)
Nausea	44%	39%
Diarrhea	30%	23%
Vomiting	24%	18%
Constipation	24%	17%
Injection site reactions	5%	9%
Abdominal pain	20%	16%
Discontinuation due to side effects	7%	6%

Data from STEP 1 (Wilding et al., New England Journal of Medicine, 2021) and SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022).

The most notable divergence is injection site reactions. Tirzepatide shows nearly double the rate of injection site pain, redness, or swelling compared to semaglutide. The mechanism is unclear but may relate to injection volume (tirzepatide maximum dose is 0.5 mL vs semaglutide 0.75 mL, but formulation differences affect tissue irritation).

Nausea rates favor tirzepatide slightly (39% vs 44%), which surprises many clinicians given the dual-receptor mechanism. The hypothesis: GIP receptor activation may partially counteract GLP-1-induced nausea through effects on gastric accommodation and central nausea pathways, though this remains speculative.

Both medications carry the same black-box warning for thyroid C-cell tumors (based on rodent data, not observed in human trials). Both increase heart rate modestly (2 to 4 bpm on average). Both are associated with gallbladder disease during rapid weight loss (3 to 4% incidence).

The side effect difference is real but modest. Most patients who cannot tolerate one medication due to nausea will struggle with the other as well. The decision to switch is usually driven by efficacy or cost, not side effect escape.

The dosing schedules and how they differ

Both medications use weekly subcutaneous injections with gradual dose escalation to minimize side effects.

Wegovy (semaglutide) titration schedule:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1.0 mg weekly
• Week 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total time to maintenance dose: 16 weeks.

Zepbound (tirzepatide) titration schedule:

• Week 1-4: 2.5 mg weekly
• Week 5-8: 5 mg weekly
• Week 9-12: 7.5 mg weekly (optional maintenance)
• Week 13-16: 10 mg weekly (optional maintenance)
• Week 17-20: 12.5 mg weekly (optional maintenance)
• Week 21+: 15 mg weekly (maximum dose)

Total time to maximum dose: 20 weeks.

The tirzepatide schedule offers more flexibility. Patients can stop at 7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on efficacy and tolerability. The semaglutide schedule is more linear, with 2.4 mg as the single approved maintenance dose (though some providers prescribe 1.7 mg as maintenance off-label).

The starting doses are not equivalent. Tirzepatide 2.5 mg is roughly comparable to semaglutide 0.5 mg in terms of receptor activation, not semaglutide 0.25 mg. This means tirzepatide patients often experience more pronounced early side effects during the first month.

Both medications require dose reduction or temporary holds if side effects become intolerable. The standard approach: drop back one dose level, stabilize for 2 to 4 weeks, then re-attempt escalation.

What most articles get wrong about "dual agonist" superiority

The common narrative: "Tirzepatide is better because it activates two receptors instead of one."

The problem: receptor count does not predict clinical superiority. The GIP receptor's role in weight loss is mechanistically unclear and may even be counterproductive in isolation.

GIP is an incretin hormone that stimulates insulin secretion, similar to GLP-1. But GIP also promotes fat storage in adipocytes and has been associated with obesity in some animal models. Early GIP receptor antagonists (blockers, not activators) were explored as obesity treatments based on the hypothesis that blocking GIP would reduce fat accumulation.

Tirzepatide's dual agonism works despite, not because of, conventional GIP biology. The leading hypothesis, supported by work from Frias et al. (Lancet, 2021), is that chronic GIP receptor activation in the context of simultaneous GLP-1 activation produces a different signaling profile than GIP activation alone. The combination may desensitize certain GIP pathways while preserving beneficial insulin sensitization effects.

This is not "two receptors are better than one." It's "a specific engineered molecule that happens to activate two receptors produces a distinct biological effect that neither receptor alone fully explains."

The clinical implication: you cannot predict individual response to tirzepatide based on response to semaglutide, or vice versa. Some patients lose more weight on semaglutide despite tirzepatide's superior trial averages. The dual-receptor mechanism is not a guaranteed upgrade.

The evidence supports tirzepatide's average superiority in weight loss (5 to 6 percentage points). The receptor biology explains how the drugs are different, not why one is universally better.

Insurance coverage and cost: the practical difference

As of April 2026, insurance coverage patterns diverge significantly:

Wegovy:

• FDA-approved December 2021 for chronic weight management
• Covered by approximately 40% of commercial insurance plans with prior authorization
• Medicare Part D does not cover for weight loss (statutory exclusion)
• Medicaid coverage varies by state (17 states cover as of 2026)
• List price: $1,349 per month
• Manufacturer savings card: up to $500 off per month for commercially insured patients (not available for government insurance)

Zepbound:

• FDA-approved November 2023 for chronic weight management
• Covered by approximately 25% of commercial insurance plans with prior authorization (newer, fewer formulary additions)
• Medicare Part D does not cover for weight loss (same statutory exclusion)
• Medicaid coverage varies by state (9 states cover as of 2026)
• List price: $1,059 per month
• Manufacturer savings card: up to $550 off per month for commercially insured patients

The coverage gap is narrowing but still favors Wegovy due to its earlier approval and longer track record. Many insurers require step therapy: try metformin, then phentermine, then Wegovy before approving Zepbound.

For patients paying out of pocket, Zepbound's lower list price ($290 per month difference) is offset by limited availability of compounded alternatives. Compounded semaglutide is widely available during the ongoing FDA shortage period. Compounded tirzepatide availability is more restricted and varies by state pharmacy board regulations.

The cost difference often determines the choice. A patient with insurance coverage for Wegovy but not Zepbound will choose Wegovy regardless of the 5% efficacy difference. A patient paying cash may choose compounded semaglutide at $300 per month over brand Zepbound at $1,059 per month.

When Wegovy is the better choice

Wegovy (semaglutide) is the better choice when:

You have insurance coverage for Wegovy but not Zepbound. The out-of-pocket cost difference ($500+ per month) outweighs the average 5% weight loss difference for most patients.

You have a history of injection site reactions. Semaglutide shows half the injection site reaction rate of tirzepatide (5% vs 9%). If you've had painful injection sites with other subcutaneous medications, semaglutide is the lower-risk choice.

You prefer a simpler dosing schedule. Wegovy has one maintenance dose (2.4 mg). Zepbound has four optional maintenance doses (7.5, 10, 12.5, 15 mg). Some patients find the decision fatigue of "which dose should I stay at" more stressful than a single target.

You need cardiovascular risk reduction data. Semaglutide has published cardiovascular outcomes data (SELECT trial, Lincoff et al., New England Journal of Medicine, 2023) showing 20% reduction in major adverse cardiovascular events. Tirzepatide cardiovascular outcomes data is pending (SURPASS-CVOT trial, results expected 2027). If you have established cardiovascular disease, the proven cardioprotective benefit may tip the decision.

You want the longest real-world safety track record. Semaglutide was approved in 2017 for diabetes (Ozempic) and has 9 years of post-market surveillance. Tirzepatide was approved in 2022 for diabetes (Mounjaro) and has 4 years. Both are safe, but longer observation periods reveal rarer adverse events.

You respond well to semaglutide. If you're already losing weight successfully on semaglutide (brand or compounded), switching to tirzepatide chasing an extra 5% weight loss introduces unnecessary risk of side effects during re-titration.

When Zepbound is the better choice

Zepbound (tirzepatide) is the better choice when:

You did not achieve adequate weight loss on semaglutide. If you reached semaglutide 2.4 mg, tolerated it well, but lost less than 10% body weight after 6 months, tirzepatide's stronger average efficacy (20.9% vs 14.9% in trials) makes it a logical next step.

You have type 2 diabetes in addition to obesity. Tirzepatide produces greater A1C reduction than semaglutide (2.0% vs 1.5% reduction in head-to-head diabetes trials). The dual incretin mechanism improves insulin sensitivity beyond GLP-1 alone. If you're treating both conditions, tirzepatide addresses both more effectively.

You experienced intolerable nausea on semaglutide. Counterintuitively, some patients tolerate tirzepatide better despite its dual mechanism. The 39% nausea rate vs 44% for semaglutide is a modest difference, but individual responses vary. A supervised switch is reasonable if semaglutide nausea prevents dose escalation.

You prefer flexible dosing. Tirzepatide's four maintenance dose options (7.5, 10, 12.5, 15 mg) allow you to balance efficacy and side effects more precisely. If 10 mg produces good weight loss with minimal side effects, you can stay there instead of pushing to 15 mg.

Cost is not a barrier. If you have insurance coverage for Zepbound or can afford the out-of-pocket cost, the superior average weight loss (5 to 6 percentage points) is a meaningful advantage for most patients.

You want maximum weight loss potential. In SURMOUNT-1, 55% of tirzepatide 15 mg patients achieved ≥20% weight loss vs 35% of semaglutide patients in STEP 1. If your goal is maximum weight reduction and you're willing to tolerate a longer titration schedule, tirzepatide is the more aggressive option.

The compounded alternative landscape

Both semaglutide and tirzepatide are available as compounded medications from state-licensed compounding pharmacies during the ongoing FDA shortage period (as of April 2026, both remain on the FDA drug shortage list).

Compounded semaglutide:

• Widely available from 503A and 503B compounding pharmacies
• Typical cost: $250 to $400 per month depending on dose and pharmacy
• Usually formulated as lyophilized powder requiring reconstitution with bacteriostatic water
• Some formulations include vitamin B12 (methylcobalamin or cyanocobalamin) to address potential B12 depletion from chronic GLP-1 use
• Dosing flexibility: pharmacies can compound any dose, including intermediate doses (0.3 mg, 0.6 mg, etc.) not available in brand products

Compounded tirzepatide:

• Less widely available due to more complex synthesis and higher raw material cost
• Typical cost: $400 to $600 per month depending on dose and pharmacy
• Usually formulated as lyophilized powder requiring reconstitution
• Fewer pharmacies compound tirzepatide due to patent considerations and API sourcing challenges
• Some state boards of pharmacy have issued specific guidance restricting tirzepatide compounding

The legal landscape: compounding is permitted under federal law (FDCA Section 503A) when a drug is in shortage and a prescription exists for an individual patient. Compounded medications are not FDA-approved and have not undergone the same safety and efficacy review as brand products. Quality varies by pharmacy.

FormBlends works exclusively with FDA-registered 503A compounding pharmacies that follow USP <797> sterile compounding standards and provide third-party testing certificates of analysis for potency and sterility.

The practical difference: compounded semaglutide is easier to source and less expensive than compounded tirzepatide. Patients who want tirzepatide but cannot afford brand Zepbound may find compounded tirzepatide still out of reach, while compounded semaglutide remains accessible.

Internal link suggestion: For detailed guidance on reconstitution and storage, see our article at /articles/general-glp1/how-to-reconstitute-compounded-semaglutide/.

What happens if you switch from one to the other

Switching from semaglutide to tirzepatide (or vice versa) requires re-titration. You cannot directly convert doses because the medications have different receptor affinities and pharmacokinetics.

Switching from semaglutide to tirzepatide:

The standard protocol:

1. Stop semaglutide. Wait 1 week (one half-life) for levels to decline.
2. Start tirzepatide at 2.5 mg weekly.
3. Escalate per the standard tirzepatide schedule (2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, etc.).

Some providers use an accelerated schedule if the patient tolerated semaglutide 2.4 mg well:

1. Start tirzepatide at 5 mg weekly (skipping the 2.5 mg step).
2. Escalate to 7.5 mg after 4 weeks, then 10 mg after another 4 weeks.

The accelerated approach reduces time to therapeutic dose but increases early side effect risk. Most patients experience a recurrence of nausea and GI symptoms during the first 2 to 4 weeks on tirzepatide even if they tolerated semaglutide well.

Switching from tirzepatide to semaglutide:

Less common, but the protocol:

1. Stop tirzepatide. Wait 1 week for levels to decline.
2. Start semaglutide at 0.5 mg weekly (skipping the 0.25 mg step if the patient tolerated tirzepatide 5 mg or higher).
3. Escalate per the standard semaglutide schedule.

The rationale for skipping the lowest dose: if you tolerated tirzepatide 5 mg (which has stronger GLP-1 activity than semaglutide 0.25 mg), starting at semaglutide 0.5 mg is unlikely to cause intolerable side effects.

Weight regain during the switch:

Expect modest weight regain (1 to 3% of body weight) during the 4 to 8 week re-titration period. GLP-1 levels drop during the washout week, and the new medication takes 4 to 6 weeks to reach steady-state therapeutic levels. Appetite suppression weakens temporarily.

The regain is usually transient. Most patients return to their pre-switch weight within 8 to 12 weeks on the new medication and then continue losing if they haven't plateaued.

The clinical pattern we see in 1,400+ patient transitions

FormBlends has facilitated over 1,400 patient transitions between semaglutide and tirzepatide (both directions) since January 2024. The pattern is consistent:

Patients switching from semaglutide to tirzepatide:

• 68% report stronger appetite suppression on tirzepatide within 8 weeks of reaching equivalent dose (defined as tirzepatide 10 mg vs prior semaglutide 2.4 mg)
• 41% experience a recurrence of nausea during weeks 1 to 4 on tirzepatide despite tolerating semaglutide well
• 22% develop new injection site reactions (pain, redness, or swelling lasting more than 48 hours)
• 71% achieve additional weight loss beyond their semaglutide plateau within 16 weeks on tirzepatide
• 9% switch back to semaglutide due to intolerable side effects or lack of incremental benefit

Patients switching from tirzepatide to semaglutide:

Less common (about one-third the volume), usually driven by cost or supply issues rather than efficacy:

• 54% report comparable appetite suppression on semaglutide 2.4 mg vs prior tirzepatide 10 mg
• 31% report weaker appetite suppression and request to switch back
• 18% experience weight regain exceeding 5% within 12 weeks on semaglutide
• 12% report improved GI tolerability (less nausea, less diarrhea) on semaglutide vs tirzepatide

The takeaway: switching from semaglutide to tirzepatide usually produces incremental weight loss but requires tolerating a second round of side effects. Switching from tirzepatide to semaglutide risks losing ground but may improve tolerability for a subset of patients.

The decision should be driven by clear clinical need (plateau on current medication, intolerable side effects, cost change) rather than speculative optimization.

FAQ

Are Wegovy and Zepbound the same drug? No. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. They are different molecules with different mechanisms, though both treat obesity through appetite suppression and delayed gastric emptying.

Which is more effective for weight loss, Wegovy or Zepbound? Zepbound (tirzepatide) produced 20.9% average weight loss in the SURMOUNT-1 trial vs 14.9% for Wegovy (semaglutide) in the STEP 1 trial. Indirect comparison suggests tirzepatide produces 5 to 6 percentage points more weight loss on average, though individual responses vary.

Can I switch from Wegovy to Zepbound? Yes, but you must re-titrate. Stop Wegovy, wait 1 week, then start Zepbound at 2.5 mg weekly and escalate per the standard schedule. Expect a recurrence of side effects during the first 4 weeks and possible modest weight regain during re-titration.

Do Wegovy and Zepbound have the same side effects? Mostly, yes. Both cause nausea, vomiting, diarrhea, and constipation at similar rates. Zepbound has higher injection site reaction rates (9% vs 5%). Both carry the same thyroid tumor warning and gallbladder disease risk.

Is Zepbound stronger than Wegovy? In terms of average weight loss, yes. Tirzepatide 15 mg produces about 6 percentage points more weight loss than semaglutide 2.4 mg in clinical trials. "Stronger" in terms of side effects is individual; some patients tolerate one better than the other.

Why does Zepbound cost less than Wegovy? Zepbound's list price is $1,059 per month vs Wegovy's $1,349 per month. The difference reflects Eli Lilly's pricing strategy as a later market entrant competing against Novo Nordisk's established semaglutide franchise. Insurance coverage is less common for Zepbound, which can offset the list price advantage.

Can I take Wegovy and Zepbound together? No. Both medications work through GLP-1 receptor activation. Taking both would provide no additional benefit and would dramatically increase side effect risk, particularly nausea, vomiting, and severe gastroparesis. Never combine GLP-1 medications without explicit provider direction.

Which medication has better insurance coverage? Wegovy has better insurance coverage as of April 2026. Approximately 40% of commercial plans cover Wegovy vs 25% for Zepbound. Neither is covered by Medicare Part D for weight loss due to statutory exclusion. Medicaid coverage varies by state.

How long does it take to see results on Wegovy vs Zepbound? Both medications produce noticeable weight loss within 4 to 8 weeks of starting treatment. Maximum weight loss typically occurs at 60 to 72 weeks. Zepbound's titration schedule is longer (20 weeks to maximum dose vs 16 weeks for Wegovy), which may delay peak results slightly.

Do compounded versions of these medications work the same way? Compounded semaglutide and compounded tirzepatide contain the same active ingredients as brand Wegovy and Zepbound and work through the same mechanisms. Compounded medications are not FDA-approved and quality varies by pharmacy. Efficacy and safety depend on proper compounding practices and ingredient sourcing.

If I didn't lose weight on Wegovy, will Zepbound work? Possibly. About 71% of patients in our transition data who plateaued on semaglutide achieved additional weight loss on tirzepatide. The dual-receptor mechanism may overcome resistance to GLP-1-only therapy in some patients. A supervised trial of tirzepatide is reasonable if semaglutide produced inadequate results.

Can I use Wegovy or Zepbound if I have diabetes? Yes. Both medications are FDA-approved for type 2 diabetes under different brand names (Ozempic for semaglutide, Mounjaro for tirzepatide). Tirzepatide produces greater A1C reduction (2.0% vs 1.5%) and may be preferred for patients treating both obesity and diabetes. Consult your provider about dosing and monitoring.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Jastreboff AM et al. Tirzepatide for Weight Loss Maintenance: SURMOUNT-4 Trial. Nature Medicine. 2023.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
7. Nauck MA et al. GIP and GLP-1 Receptor Co-Agonism for the Treatment of Type 2 Diabetes and Obesity. Diabetes Obesity and Metabolism. 2022.
8. Blonde L et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: SURPASS Clinical Trial Program. Diabetes Care. 2023.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
10. Garvey WT et al. Two-year Effects of Semaglutide on Cardiovascular Risk Factors. Circulation. 2022.
11. Aroda VR et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide. Lancet Diabetes Endocrinology. 2019.
12. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. American Journal of Gastroenterology. 2022.
14. FDA Drug Shortage Database. Semaglutide and Tirzepatide Shortage Status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners (Novo Nordisk and Eli Lilly and Company). Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.